<DOC>
	<DOCNO>NCT02410187</DOCNO>
	<brief_summary>Clinical experience show metastasis often limited number location , thus amenable local treatment . The term oligometastasis describes intermediate state cancer spread localize disease widespread metastasis . The implication intermediate state disease cure use metastasis-directed therapy . Historically , patient oligometastases liver lung , surgical resection often indicate , abundant evidence suggest could improve progression-free overall survival . Recently , several study report promising outcome &gt; 80 % local control Stereotactic Body Radiotherapy ( SBRT ) patient lung liver oligometastases . Nonetheless , study focus non-liver , non-lung extracranial oligometastatic lesion treat SBRT , study limitation retrospective nature small sample sizes.Because allmost study base single-arm study without appropriate control , level evidence support SBRT weak . Randomized trial therefore necessary establish utility SBRT oligometastatic disease . This study design randomize phase II study . Patients randomize current standard treatment ( Arm 1 ) versus standard treatment +SBRT ( Arm 2 ) know disease .</brief_summary>
	<brief_title>SBRT Extra-cranial Oligorecurrent Tumor</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<criteria>age &lt; 18 year old ECOG score : 02 number distant metastasis : 15 cancer ( except lymphoma , myeloma , germ cell tumor ) status primary lesion : cure pathologically confirm cancer life expectancy : 6 month recurrent lesion treat radiotherapy complete response systemic therapy patient treat SBRT due reason . pregnancy breastfeed malignant pleural effusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>stereotactic body radiotherapy</keyword>
</DOC>